The Use of an IL-1 Receptor Antagonist Peptide to Control Inflammation in the Treatment of Corneal Limbal Epithelial Stem Cell Deficiency

Figure 2

(a) LDH was measured to assess the cytotoxic effect of keratocyte treatment with increasing concentrations of peptide (0.01–1000 μg/mL). (b) MTS conversion to formazan was measured to assess peptide impact on keratocyte metabolism treated as in (a). No significant difference was shown in peptide treated groups compared to nontreated controls () (, mean ± sd).

(a)

(b)